Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety, Tolerability and Pharmacokinetic Study of HRS-8829
Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
Summary
This study adopted a single-center, randomized, double-blind, placebo-controlled, dose-escalation design and was divided into two parts: single-dose dose-escalation (SAD) and multiple-dose dose-escalation (MAD)
Official title: Safety, Tolerability and Pharmacokinetic Studies of Single and Multiple Administrations of HRS-8829 in Healthy Subjects
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2025-07
Completion Date
2025-11
Last Updated
2025-07-24
Healthy Volunteers
Yes
Conditions
Interventions
HRS-8829;Placebo
Subject will receive HRS-8829 at dose level 1. Subject will receive placebo at dose level 1.
HRS-8829;Placebo
Subject will receive HRS-8829 at dose level 2. Subject will receive placebo at dose level 2.
HRS-8829;Placebo
Subject will receive HRS-8829 at dose level 3. Subject will receive placebo at dose level 3.
HRS-8829;Placebo
Subject will receive HRS-8829 at dose level 4. Subject will receive placebo at dose level 4.
Locations (1)
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China